Business & Finance
Kymab receives USD100m funding to advance range of therapeutic human monoclonal antibodies
28 November 2016 -

Kymab, a United Kingdom-based biopharmaceutical company, has received USD100m in funding to advance its range of therapeutic human monoclonal antibodies, it was reported on Friday.

ORI Healthcare Fund headed the Series C financing with participation by Shenzhen Hepalink Pharmaceutical. Existing shareholders, Wellcome Trust, Bill & Melinda Gates Foundation, Malin Corporation, CF Woodford Equity Income Fund and Woodford Patient Capital have also made follow-on investments.

The latest round follows the USD120m Series A & B financings received by Kymab, which is utilising the Kymouse transgenic human antibody platform for the discovery and development of fully human monoclonal antibody drugs.

Kymab, which started operations in 2010, has to date raised more than USD220m of equity financing.

Login
Username:

Password: